MNTA News and Press, Momenta Pharmaceuticals Inc. From 06/10/20

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Despite disruptions from the COVID-19 pandemic, Momenta Pharmaceuticals ' (NASDAQ: MNTA) clinical trials investigating experimental therapies for a variety of autoimmune conditions and rare diseases are still going strong. The company will be announcing top-line phase 2 results for the treat...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Momenta Pharmaceuticals, Inc. (MNTA) Q1 2020 Results Conference Call May 07, 2020 08:30 AM ET Company Participants Patty Eisenhaur - VP, IR and Communications Craig Wheeler - President and CEO Young Kwon - Chief Financial and Business Officer Santiago Arroyo - Chief Medical Off...

Image source: The Motley Fool. Momenta Pharmaceuticals Inc   (NASDAQ: MNTA) Q1 2020 Earnings Call May 7, 2020 , 8:30 a.m. ET Operator Continue reading

Momenta Pharmaceuticals (NASDAQ: MNTA ): Q1 GAAP EPS of -$0.34 beats by $0.15 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Top-line interim data from nipocalimab Vivacity-MG study expected by Q3 2020 -- -- Full data from Part B of Phase 1/2 study of M254 in ITP expected in Q3 2020 -- -- Initiated IND-enabling studies for M267, a SIFbody candidate targeting CD38 -- CAMBRIDGE, Mass., May 07, 2020 ...

Year to date, shares of Regeneron Pharmaceuticals (NASDAQ: REGN) have gained nearly 50% despite significant declines in the overall market. Arguably, strong growth from its core pipeline consisting of Eylea (eye injection used to treat various forms of retinal disorders) and Dupixent (biol...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...